Intellia Therapeutics
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Intellia Therapeutics
RECRUITINGPhase 3NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Sponsor: Intellia TherapeuticsEnrolling: 120020 locations
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
RECRUITINGNCT05697861
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Sponsor: Intellia TherapeuticsEnrolling: 724 locations
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis